Hong Kong-listed biopharmaceutical stocks rose in early trading, with Zai Lab (09688.HK) up more than 8.5%, Kelun Biotech (06990.HK) up nearly 6%, BeiGene (06160.HK) up more than 4%, Rongchang Biopharmaceuticals (09995.HK), WuXi Biologics (02269.HK), InnoCare Pharma (09969.HK), and WuXi AppTec (02359.HK) all up more than 3%.

2025-06-12 09:55:06

BeiGene WuXi Biologics WuXi AppTec

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Southbound funds made a large net purchase of 5.743 billion yuan today. In terms of Hong Kong Stock Connect (Shanghai), China Construction Bank and Meituan-W received net purchases of HK$1.108 billion and HK$493 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$1.489 billion; in terms of Hong Kong Stock Connect (Shenzhen), Meituan-W and Kangfang Biopharma received net purchases of HK$622 million and HK$206 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$391 million.
                            2025-06-16

                                    Arm (ARM.O): We are better than Nvidia on a wider range of platforms.
                            2025-06-12

                                    Lei Jun: Xiaomi Yu7 will be released at the end of June
                            2025-06-16

                                    Putin: Russia will create unmanned system forces as a separate branch of the military
                            2025-06-13

                                    Barclays: Raised Oracle (ORCL.N) price target from $202 to $221.
                            2025-06-13